23 research outputs found
An Overview of The VERITAS Prototype Telescope And Camera
VERITAS (the Very Energetic Radiation Imaging Telescope Array System) is the
next generation ground-based gamma-ray observatory that is being built in
southern Arizona by a collaboration of ten institutions in Canada, Ireland, the
U.K. and the U.S.A. VERITAS is designed to operate in the range from 50 GeV to
50 TeV with optimal sensitivity near 200 GeV; it will effectively overlap with
the next generation of space-based gamma-ray telescopes. The first phase of
VERITAS, consisting of four telescopes of 12 m aperture, will be operational by
the time of the GLAST launch in 2007. Eventually the array will be expanded to
include the full array of seven telescopes on a filled hexagonal grid of side
80 m. A prototype VERITAS telescope with a reduced number of mirrors and signal
channels has been built. Its design and performance is described here. The
prototype is scheduled to be upgraded to a full 499 pixel camera with 350
mirrors during the autumn of 2004.Comment: 8 pages, 6 figures, Proceedings of the Conference "The
Multiwavelength Approach to Unidentified Sources", to appear in the journal
Astrophysics and Space Scienc
Correlated variability of Mkn 421 at X-ray and TeV wavelengths on timescales of hours
Mkn 421 was observed for about two days with BeppoSAX, prior to and partly
overlapping the start of a 1 week continuous exposure with ASCA in April 1998,
as part of a world-wide multiwavelength campaign. A pronounced, well defined,
flare observed in X-rays was also observed simultaneously at TeV energies by
the Whipple Observatory's 10 m gamma-ray telescope. These data provide the
first evidence that the X-ray and TeV intensities are well correlated on
time-scales of hours.Comment: 4 pages, 1 figure, presented at the VERITAS Workshop on the TeV
Astrophysics of Extragalactic Object
A High Statistics Search for Ultra-High Energy Gamma-Ray Emission from Cygnus X-3 and Hercules X-1
We have carried out a high statistics (2 Billion events) search for
ultra-high energy gamma-ray emission from the X-ray binary sources Cygnus X-3
and Hercules X-1. Using data taken with the CASA-MIA detector over a five year
period (1990-1995), we find no evidence for steady emission from either source
at energies above 115 TeV. The derived upper limits on such emission are more
than two orders of magnitude lower than earlier claimed detections. We also
find no evidence for neutral particle or gamma-ray emission from either source
on time scales of one day and 0.5 hr. For Cygnus X-3, there is no evidence for
emission correlated with the 4.8 hr X-ray periodicity or with the occurrence of
large radio flares. Unless one postulates that these sources were very active
earlier and are now dormant, the limits presented here put into question the
earlier results, and highlight the difficulties that possible future
experiments will have in detecting gamma-ray signals at ultra-high energies.Comment: 26 LaTeX pages, 16 PostScript figures, uses psfig.sty to be published
in Physical Review
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Background:
In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation.
Methods:
This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936).
Findings:
Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001).
Interpretation:
In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids.
Funding:
UK Research and Innovation (Medical Research Council) and National Institute of Health Research
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Background:
Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19.
Methods:
This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.
Findings:
Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79).
Interpretation:
In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes.
Funding:
UK Research and Innovation (Medical Research Council) and National Institute of Health Research
Detection of Gamma Rays with E > 100 MeV from BL Lacertae
Original article can be found at: http://www.journals.uchicago.edu/ApJ/--Copyright American Astronomical SocietyPeer reviewe